ORHB - 4 Orthobiologic Stocks Set To Soar In 2024
(NewsDirect)
Welcome to the transformative landscapeof orthobiologics, where cutting-edge treatments utilize thebody's own cells and healing factors to reverse orthoarthritiseffects and expedite recovery from tendon and ligament injuries. Theseinnovations, naturally derived and featuring stem cells, represent aparadigm shift in healthcare.
In theglobal orthobiologics market, anticipated to reach US$6,515.2 millionby 2022 with a 5.9% CAGR until 2030, key drivers include a risinggeriatric population, increased spine abnormalities, and advancementsin stem cell therapies. Companies are pioneering bone graftsubstitutes and minimally invasive procedures, driving marketexpansion.
As we delve into thisexciting and growing market, let's explore four key players poisedto make significant strides in the ever-evolving field oforthobiologics.
In the dynamiclandscape of regenerative therapeutics, HippoFi Inc. (OTC:ORHB) emerges as a pivotal player, strategically navigating theburgeoning orthobiologics sector with a primary focus on the spine,orthopedic, and cancer markets. As a healthcare innovator, thispublicly traded company actively advances patient care and outcomesthrough the seamless integration of biotech and AI technologies.
HippoFi's operations revolve aroundthree key business segments: digital payments, artificialintelligence, and regenerative therapeutics. At the forefront of itsregenerative therapeutic endeavors is PUR Biologics, a wholly-ownedsubsidiary dedicated to pioneering innovative biological products andproprietary technologies. The company's mission is clear: toaddress degenerative and diseased conditions, significantly improvingthe quality of life for patients.
Within the vast $1.37 trillion biotechnology market, PURBiologics stands out by actively developing scalable biologicalsolutions. Forging strategic partnerships with industry giants such asZIMMER/BIOMET, Hoag Hospital Newport Beach, BPB Medica, PrecisionSpine, and others, PUR Biologics advances technologies that enhancebone growth, regenerate joint cartilage, and offer cutting-edgecell-based immunotherapy for cancer treatment.
On September 6, HippoFi, in collaborationwith Zimmer Biomet Holdings Inc. (NYSE: ZBH), unveiled a strategicpartnership aimed at introducing a novel synthetic biomaterial forbone growth under PUR Biologics in 2024. This collaborationunderscores the company's unwavering commitment to reshaping thespinal biologics landscape.
Apivotal moment for PUR Biologics occurred on September 12 when itsecured a groundbreaking patent, signaling advancements in painrelief, bone regeneration, anti-cancer therapies, and more. Thepatented device, designed to enhance the body's immune response,holds significant promise in the rapidly growing spine industry,projected to reach $40 billion by 2027.
The emergence of PURmarrow360, a revolutionary surgical deviceby HippoFi, takes center stage, specifically designed to capture apatient's own bone marrow aspirate and mesenchymal stem cells.This innovation adds a disruptive edge to the spinal biologics market,positioning PUR Biologics at the forefront of transformativetechnologies.
In November, HippoFiannounced a significant international sales win, expanding its salesto include several notable international healthcare establishments.The Head of PUR Biologics, Ryan Fernan, attributed this success torecent ventures with ZIMMER BIOMET and Italian company BPB Medica,garnering broader international attention.
In a strategic move on November 7, Dr. Gail Naughton, aworld-renowned authority in regenerative medicine, joined HippoFi asthe Head of Regenerative Therapeutics and Commercialization. With aproven track record in tissue engineering and regenerative medicine,Dr. Naughton's appointment strengthens HippoFi's position inaddressing unmet needs in the $200 billion osteoarthritis, pain, andcartilage, as well as spinal disc regeneration markets.
On December 5, HippoFi announced asignificant expansion in California, underscoring its commitment toproviding healthcare professionals and patients with the highest levelof service and quality. PUR Biologics, known for its suite ofbest-in-class spinal biologics, is poised to be a leader in the fieldof spinal biologics.
Closing out theyear on December 11, HippoFi's wholly-owned subsidiary, PURBiologics, made a significant stride by breaking into theinternational market and selling and shipping products forinternational use. The company anticipates robust sales growth in2024, tracking over $20 million in revenue.
In summary, HippoFi Inc. (OTC: ORHB)demonstrates dynamic growth and innovation in the rapidly evolvingorthobiologics sector, with strategic partnerships, groundbreakingtechnologies, and a robust track record paving the way for continuedsuccess in the field of regenerative therapeutics.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) takes center stage as a global leader in medical technology,specializing in orthopedic reconstructive products. With a rich legacyspanning 90+ years, the company stands poised for exponential growthin the coming years.
In the thirdquarter of 2023, Zimmer Biomet reported robust financials, boasting a5.0% increase in net sales, reaching $1.754 billion. Net earnings of$162.7 million (adjusted to $346.5 million) underscore thecompany's financial strength and resilience.
A key driver of Zimmer Biomet'ssuccess lies in its strategic leadership changes. The appointment ofCEO Ivan Tornos reflects a commitment to innovation and commercialexecution, positioning the company for continued growth. Furtherleadership updates, including the expanded role of CFO SuketuUpadhyay, underscore a proactive approach to navigating the dynamichealthcare landscape.
ZimmerBiomet's dedication to innovation is evident in milestones such asenrolling 100,000 patients on the mymobility care management platform.This platform integrates automation, data, and insights, enhancing theorthopedic patient experience.
Recognized for its Environmental, Social, and Governance (ESG)initiatives, Zimmer Biomet finds itself on prestigious lists likeNewsweek Americas Greenest Companies 2024 and the SustainabilityMagazine Top 10: Sustainable Healthcare Device Companies.
In a gesture towards shareholders, ZimmerBiomet's Board of Directors approved a quarterly cash dividend of$0.24 per share for Q4 2023, reinforcing the company's commitmentto delivering value.
In conclusion,Zimmer Biomet emerges as a dynamic force in orthopedic advancements,blending financial prowess, strategic leadership, innovation, andshareholder value. As the healthcare landscape evolves, Zimmer Biometstands resilient, shaping the future of medical technology.
Based in Audubon, Pennsylvania, GlobusMedical, Inc. (NYSE: GMED) has been a pioneering force in medicaltechnology since its founding in 2003. The company's core missionis to develop innovative products that empower surgeons to enhancehealing in patients with musculoskeletal disorders.
Globus Medical has a market capitalizationof $6.81 billion and is poised for growth, owing primarily to thesuccess of its U.S. spine and trauma portfolios. Despite encounteringmacroeconomic challenges affecting profit margins, the company hasexperienced a noteworthy 31.2% stock increase over the pastyear.
With a long-term estimatedearnings growth rate of 11.5%, slightly below the industry average of13.3%, GMED has consistently outperformed earnings estimates,delivering an average surprise of 5.44% in the last fourquarters.
In terms of strategicupsides, GMED reported a 10.7% increase in musculoskeletal revenues inthe third quarter. This success is attributed to the launch ofinnovative products like REFLECT, MARVEL, and Ossifuse, withexpectations of a robust series of product launches throughout theMusculoskeletal portfolio in 2024.
The company maintains a strong focus on product development, asevidenced by the launch of the Precice Bone Transport system, Hydrone,and the Strato wiring system for trauma in September 2023. Surgeonscan anticipate access to an expanding array of offerings, including a3D-printed interbody portfolio, cervical discs, robotic prone andlateral systems, EGPS E3D, neuromonitoring solutions, retractors, andlimb-lengthening products.
Financially resilient, GMED ended Q3 2023 with $468.9 million incash and short-term marketable securities, showcasing strongliquidity, solvency, and a debt-free balance sheet.
Globus Medical, Inc.'s strategicfocus, financial stability, and innovative nature have kept it a majorplayer in the musculoskeletal industry. The company's trajectoryof product launches and advancements positions it for sustained growthand impact in the medical device industry.
Stryker Corporation (NYSE: SYK) is a leader in medicaltechnology with a global focus, committed to improving healthcareoutcomes across the board. With an extensive portfolio spanningmedical and surgical, neurotechnology, orthopaedics, and spine, thecompany impacts over 130 million patients annually.
The company's resilience is evident inits strong performance across U.S. segments, supported by equallypromising international sales. As of the third quarter of 2023,Stryker reported encouraging financials, emphasizing a 3.5% earningsyield, surpassing the industry standard of 2.1%.
Mako, an innovative robotic arm-assistedsurgery platform, and SYK's diverse product portfolio contributeto the company's strong performance. With a market capitalizationof $113.1 billion, Stryker anticipates a 10.1% improvement in earningsover the next five years, outpacing the industry's average.
Stryker's strategic focus on thecontinued expansion of Mako sets the stage for growth, with plannedlaunches in new countries. The company remains confident in the robustgrowth of Mako revenues through ongoing adoption, new launches, andsoftware upgrades throughout 2023.
The recent third-quarter results highlighted Stryker'scommitment to advancing the field of surgery through its innovativeplatform. The firm expects sustained momentum through the fourthquarter of 2023, fueled by procedural recovery, a robust order bookfor capital equipment, and improved pricing.
SYK's diversified product portfoliopositions it well to weather economic challenges, ensuring stabilityand mitigating significant sales shortfalls.
In conclusion, Stryker Corporation (NYSE:SYK) emerges as a stalwart in medical technology, blending innovation,financial strength, and a commitment to global healthcare improvement.With a strategic vision for sustained growth, Stryker stands as atop-tier performer in the ever-evolving landscape of large-cap Medtechcompanies.
Disclaimers: The Private Securities Litigation ReformAct of 1995 provides investors a safe harbor in regard toforward-looking statements. Any statements that express or involvediscussions with respect to predictions, expectations, beliefs, plans,projections, assumptions, objectives, goals, or assumptions of futureevents or performance are not statements of historical fact may beforward looking statements. Forward looking statements are based onexpectations, estimates, and projections at the time the statementsare made that involve a number of risks and uncertainties which couldcause actual results or events to differ materially from thosepresently anticipated. Forward looking statements in this action maybe identified through use of words such as projects, foresee, expects,will, anticipates, estimates, believes, understands, or that bystatements, indicating certain actions & quotes; may, could ormight occur Understand there is no guarantee past performance isindicative of future results. Investing in micro-cap or growthsecurities is highly speculative and carries an extremely high degreeof risk. It is possible that an investor's investment may be lostor due to the speculative nature of the companies profiled. CapitalGains Report (CGR), owned by RazorPitch Inc., is responsible for theproduction and distribution of this content. CGR is not operated by alicensed broker, a dealer, or a registered investment advisor. Itshould be expressly understood that under no circumstances does anyinformation published herein represent a recommendation to buy or sella security. CGR has been retained by HippoFi Inc to produce anddistribute this content. As part of that content, readers,subscribers, and webs are expected to read the full disclaimers andfinancial disclosure statement that can be found on our websitecapitalgainsreport.com All content in this article is information of ageneral nature and does not address the circumstances of anyparticular individual or entity. Nothing in this article constitutesprofessional and/or financial advice, nor does any information in thearticle constitute a comprehensive or complete statement of thematters discussed or the law relating thereto. CGR is not a fiduciaryby virtue of any persons use of or access to thiscontent.
Contact Details
Mark McKelvie
+1585-301-7700
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.